Abstracts accepted for the 2009 ASCO Annual Meeting

Eighteen EORTC abstracts have been accepted for presentation at the 2009 ASCO Annual meeting to be held 29 May to 2 June, 2009 in Orlando, Florida. A listing of these abstracts is given below.

Oral Abstract Presentation Session

Radiation Oncology and Brain Tumor Groups

Abstract ID 2008 (selected to be included in the Best of ASCO® program)
Adjuvant Whole Brain Radiotherapy versus Observation after Radiosurgery or Surgical Resection of 1-3 Cerebral Metastases – Results of the EORTC 22952-26001 Study. R. P. Mueller, R. Soffietti, M.U. Abacioglu, S. Villa, F. Fauchon, B.G. Baumert, L. Fariselli, T. Tzuk-Shina, S. Collette, M. Kocher.

EORTC Gastrointestinal Tract Cancer Group

Abstract ID 4510 (selected to be included in the Best of ASCO® program)
Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia: Randomized EORTC Phase III Trial. C. Schuhmacher, P.M. Schlag, F. Lordick, W. Hohenberger, J. Heise, C. Haag, S. Gretschel, M. Mauer, M.P. Lutz, J.R. Siewert.

EORTC Gynecological Cancer Group

Abstract ID 30412
A randomised trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials). G.J. Rustin, M.E. van der Burg, on behalf of MRC and EORTC collaborators; Mount Vernon Cancer Centre, Middlesex, United Kingdom; Erasmus MC University Medical Center, Rotterdam, Netherlands.

EORTC Melanoma Group

Abstract ID 90007
Ulceration of primary melanoma and responsiveness to adjuvant interferon therapy: analysis of the adjuvant trials EORTC 18952 and EORTC18991 in 2644 patients. A. M. Eggermont, S. Suciu, A. Testori, P. Patel, A. Spatz.

Poster Discussion Session

EORTC Soft Tissue and Bone Sarcoma Group

Abstract ID 10536
Type of progression in patients treated with imatinib for advanced gastro-intestinal stromal tumors (GIST): a study based on the EORTC-ISG-AGITG trial 62005. M. M. Van Glabbeke, J. Verweij, P. Casali, J. Zalcberg, A. Le Cesne, P. Reichardt, R. Issels, I. Judson, M. Debiec-Rychter, J. Y. Blay.

EORTC Soft Tissue and Bone Sarcoma Group

Abstract ID 10520
Combined analysis of two phase II trials of imatinib in advanced dermatofibrosarcoma protuberans (DFSP). S. Schuetze, P. Rutkowski, M.M. Van Glabbeke, C. Rankin, B. P. Rubin, A. Lazar, M. Debiec-Rychter, H. Gelderblom, W. Ruka, A. T. van Oosterom.

Gastrointestinal Tract Cancer Group

Abstract ID 4527
Adjuvant gemcitabine alone versus gemcitabine-based chemoradiation after curative resection for pancreatic cancer: updated results of a randomized EORTC/FFCD/GERCOR phase II study (40013-22012/9203). J. L. Van Laethem, F. Mornex, D. Azria, G. van Tienhoven, M. Mauer, M. Praet, V. Budach, P. Hammel, E. Van Cutsem, K. Haustermans.

Lung Cancer Group

Abstract ID 7509
Phase II feasibility trial of induction chemotherapy (ICT) followed by extrapleural pneumonectomy (EPP) and postoperative radiotherapy (PORT) for cT3N1M0 or less malignant pleural mesothelioma (MPM) (EORTC 08031). P.E. Van Schil, P. Baas, R. Gaafar, A.P. Maat, M. van de Pol, B. Hasan, H.M. Klomp, A.M. Abdelrahman, J. Welch, J. Van Meerbeeck.

General Poster Session

EORTC Quality of Life

Abstract ID 9612
Relationships among Health-Related Quality of Life indicators in cancer patients: a pooled study of baseline EORTC QLQ-C30 data from 6739 patients. F. Martinelli, C. Quinten, C. Coens, H. Flechtner, C. Gotay, T. Mendoza, D. Osoba, B. Reeve, X. Wang, A. Bottomley.

EORTC Quality of Life

Abstract ID 9607
The predictive accuracy of survival between patient- versus clinician- reported pain in a cohort of 1214 patients with metastatic cancer. C. Quinten, F. Martinelli, C. Coens, C. Cleeland, H. Flechtner, C. Gotay, E. Greimel, M. Taphoorn, J. Weis, A. Bottomley.

EORTC Quality of Life

Abstract ID 9597
Is patient self-reporting more accurate than clinician reporting of symptoms for predicting survival in patients with cancer? Meta-analysis of 30 closed EORTC Randomized Controlled Trials. A. Bottomley, C. Coens, M. King, D. Osoba, M. Taphoorn, B. Reeve, J. Ringash, J. Schmucker-Von Koch, J. Weis, C. Quinten.

EORTC Quality of Life

Abstract ID 30898
Heath-related quality of life (HRQOL) in a non-small cell lung cancer (NSCLC): an update of a systematic review on methodological issues in randomized controlled trials (RTCs). L. Claassens, J. van Meerbeeck, C. Coens, C. Quinten, X.S. Wang, G. Veikova, A. Bottomley.

EORTC Head and Neck Cancer Group

Abstract ID 6017
EORTC 24051: Unexpected side effects of a phase I study of TPF induction chemotherapy (IC) followed by chemoradiation (CRT) with lapatinib (LAP), a dual EGFR/ErbB2 inhibitor, in patients with locally advanced larynx and hypopharynx squamous cell carcinoma (LA-LxHxSCC). P.M. Specenier, Y. Lalami, J. Vermorken, D. Lacombe, I. El-Hariry, J. Bogaerts, A. Awada.

EORTC Head and Neck Cancer Group

Abstract ID 6075
TPF versus as induction therapy in unrespectable head and neck cancer: a pharmacoeconomic analysis. Nicola Lucio Liberato, Jan Bogaerts, Giulio Danese, Monia Marchetti, Silavana Quaglini, Carla Rognoni, Stefania Rubrichi, Lisa Licitra, Jan Vermorken.

EORTC Soft Tissue and Bone Sarcoma Group

Abstract ID 10573
Prognostic factors in Adolescents and Young Adults (AYA) with high risk Soft Tissue Sarcoma (STS) treated by adjuvant chemotherapy: A study based on two pooled European Organisation for Research and Treatment of Cancer (EORTC) clinical trials. B. Kasper, M. Ouali, M. Van Glabbeke, J. Y. Blay, V. H. Bramwell, P. J. Woll, P. Schöffski.

EORTC Gastrointestinal Group

Abstract ID 4002
Stage-specific prognostic value of molecular markers in colon cancer: Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial. A. Roth.

Publication Only

EORTC Quality of Life

Abstract ID e20576
Health-Related Quality of Life indicators and overall Quality of Life: results from a cluster analysis on baseline EORTC QLQ-C30 data from 6739 cancer patients. C. Coens, F. Martinelli, C. Quinten, C. Cleeland, E. Greimel, M. King, J. Ringash, J. Schmucker-Von Koch, Q. Shi, A. Bottomley.

EORTC Brain Tumor Group

Abstract ID e13005
Phase I Study of LY317615 (Enzastaurin) and temzolomide in patients with gliomas – EORTC trial 26054. Roy Rampling, Marc Sanson, Walter Taal, Christina Lai, Clemens Stoffregen, Maria Munoz, Thierry Gorlia, Ann Sophie Govaerts, Denis Lacombe, Martin van den Bent.

John Bean
Stéphanie Vandergooten

Back to news list

Related News

  • We are pleased to announce the release of the EORTC 2023 Annual Report

  • Dr Denis Lacombe, EORTC CEO, appointed stakeholder co-chair of ACT EU advisory group

  • Clinical Trials Day 2024: a Q&A on pragmatic clinical trials

  • EORTC/EMA workshop suggests an international way forward for treatment optimisation studies

  • EORTC’s Participation at the ESTRO Congress 2024

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)